Present an evidenced route decision, a matched economic comparison and an executable continuity plan. Keep unresolved eligibility and quality questions outside the weighted commercial score.
Recommended approval pack:
- Decision: exact arrangement, products, facilities and patient population.
- Control of spending: clinic costs separated from patient and insurer expenditure.
- Eligibility: dated clinical, legal and state-permission review.
- Quality: evidence register, findings and unresolved requests.
- Economics: matched scenarios, ongoing prices and sensitivities.
- Operations: pilot results, responsibilities and service definitions.
- Resilience: dependencies, tested alternatives and transition plan.
- Contract exposure: minimums, deposits, remedies and exit costs.
- Monitoring: named owners and reconsideration triggers.
What should the team do over the next 30 days?
- Week 1: map current arrangements, payment flows and failure data.
- Week 2: issue one standardized evidence request and quotation template.
- Week 3: complete specialist review and test shortlisted workflows.
- Week 4: reconcile the cost model, negotiate protections and approve only the supported scope.
Immediate stop conditions: unidentified performing entity, unresolved product identity, unsupported route justification, material unaddressed quality concern or inability to reconcile patient orders.
The objective is not the cheapest advertised medicine. It is a defensible arrangement whose costs, responsibilities and failure modes the clinic understands.
Sources cited on this page
See the section’s source register for the research context.
Section sources →